FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996319504> ?p ?o ?g. }

• W2996319504 endingPage "1205" @default.
• W2996319504 startingPage "1199" @default.
• W2996319504 abstract "Although there is abundant evidence of vascular perturbation from studies of peripheral blood in systemic sclerosis (SSc), there are few data about the ability to use biomarkers of vascular injury and growth factors to predict vascular outcomes and response to therapy. We sought to explore the association between candidate vascular biomarkers and digital ulcerations (DU) in a clinical trial context.We examined 19 circulating vascular, angiogenic, and inflammatory biomarkers in 124 patients with scleroderma and DU who participated in a randomized controlled trial of oral treprostinil diolamine (ClinicalTrials.gov identifier NCT00775463). Correlation, regression, and random forest analyses were conducted to assess biomarker relationships in response to drug treatment.Over the 20-week trial, 82 (66%) patients had their cardinal ulcer completely heal, 54 (44%) developed new ulcers, and 72 (58%) had complete healing of all ulcers; mean change in ulcer burden comparing week 20 with baseline was - 0.36 ± 1.70. Nineteen biomarkers were analyzed for their association and ability to predict clinical DU outcomes. After adjusting for multiple comparisons, no individual biomarker (baseline level, week 20 level, or change over time) was significantly associated with any of the clinical outcomes, suggesting that traditional vascular, angiogenic or inflammatory drivers are not predictive of ulcer fate.The lack of strong response to any of the vascular, angiogenic, or inflammatory markers suggest that these pathways are not primary drivers in the development of DU clinical outcomes in a SSc population with prevalent DU.• Currently we lack robust biomarkers to predict vascular outcomes or response to therapy in scleroderma patients with Raynaud's phenomenon.• Longitudinal assessment of vascular biomarkers in a clinical trial setting provides a unique opportunity to define biomarkers that predict vascular outcomes.• In a randomized controlled trial of oral treprostinil diolamine for treatment of scleroderma-associated digital ulcers, biomarkers involved in several vascular, inflammatory, and angiogenic pathways did not predict short-term clinical response to therapy or digital ulcer outcomes.• Further study of these and other biomarkers should be considered in Raynaud's clinical trials in scleroderma patients without prevalent digital ulcers." @default.
• W2996319504 created "2019-12-26" @default.
• W2996319504 creator A5000968299 @default.
• W2996319504 creator A5001518244 @default.
• W2996319504 creator A5006172726 @default.
• W2996319504 creator A5009211703 @default.
• W2996319504 creator A5025020248 @default.
• W2996319504 creator A5042603098 @default.
• W2996319504 creator A5056428172 @default.
• W2996319504 creator A5068528030 @default.
• W2996319504 creator A5071880070 @default.
• W2996319504 creator A5086359066 @default.
• W2996319504 date "2019-12-19" @default.
• W2996319504 modified "2023-10-10" @default.
• W2996319504 title "Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1)" @default.
• W2996319504 cites W1867518600 @default.
• W2996319504 cites W2004772035 @default.
• W2996319504 cites W2006617902 @default.
• W2996319504 cites W2011072396 @default.
• W2996319504 cites W2028629828 @default.
• W2996319504 cites W2034204078 @default.
• W2996319504 cites W2037339637 @default.
• W2996319504 cites W2061339987 @default.
• W2996319504 cites W2068395509 @default.
• W2996319504 cites W2077002404 @default.
• W2996319504 cites W2084272592 @default.
• W2996319504 cites W2094444470 @default.
• W2996319504 cites W2098238896 @default.
• W2996319504 cites W2104826645 @default.
• W2996319504 cites W2115098571 @default.
• W2996319504 cites W2128443991 @default.
• W2996319504 cites W2151293400 @default.
• W2996319504 cites W2276620411 @default.
• W2996319504 cites W2425216987 @default.
• W2996319504 cites W2463285017 @default.
• W2996319504 cites W2468381947 @default.
• W2996319504 cites W2489601078 @default.
• W2996319504 cites W2581082906 @default.
• W2996319504 cites W2590943996 @default.
• W2996319504 cites W2619900942 @default.
• W2996319504 cites W2806446597 @default.
• W2996319504 cites W4250041251 @default.
• W2996319504 doi "https://doi.org/10.1007/s10067-019-04863-0" @default.
• W2996319504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8211019" @default.
• W2996319504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31858338" @default.
• W2996319504 hasPublicationYear "2019" @default.
• W2996319504 type Work @default.
• W2996319504 sameAs 2996319504 @default.
• W2996319504 citedByCount "5" @default.
• W2996319504 countsByYear W29963195042020 @default.
• W2996319504 countsByYear W29963195042022 @default.
• W2996319504 countsByYear W29963195042023 @default.
• W2996319504 crossrefType "journal-article" @default.
• W2996319504 hasAuthorship W2996319504A5000968299 @default.
• W2996319504 hasAuthorship W2996319504A5001518244 @default.
• W2996319504 hasAuthorship W2996319504A5006172726 @default.
• W2996319504 hasAuthorship W2996319504A5009211703 @default.
• W2996319504 hasAuthorship W2996319504A5025020248 @default.
• W2996319504 hasAuthorship W2996319504A5042603098 @default.
• W2996319504 hasAuthorship W2996319504A5056428172 @default.
• W2996319504 hasAuthorship W2996319504A5068528030 @default.
• W2996319504 hasAuthorship W2996319504A5071880070 @default.
• W2996319504 hasAuthorship W2996319504A5086359066 @default.
• W2996319504 hasBestOaLocation W29963195042 @default.
• W2996319504 hasConcept C126322002 @default.
• W2996319504 hasConcept C151730666 @default.
• W2996319504 hasConcept C168563851 @default.
• W2996319504 hasConcept C185592680 @default.
• W2996319504 hasConcept C198451711 @default.
• W2996319504 hasConcept C2779343474 @default.
• W2996319504 hasConcept C2781197716 @default.
• W2996319504 hasConcept C2908647359 @default.
• W2996319504 hasConcept C535046627 @default.
• W2996319504 hasConcept C55493867 @default.
• W2996319504 hasConcept C71924100 @default.
• W2996319504 hasConcept C86803240 @default.
• W2996319504 hasConcept C99454951 @default.
• W2996319504 hasConceptScore W2996319504C126322002 @default.
• W2996319504 hasConceptScore W2996319504C151730666 @default.
• W2996319504 hasConceptScore W2996319504C168563851 @default.
• W2996319504 hasConceptScore W2996319504C185592680 @default.
• W2996319504 hasConceptScore W2996319504C198451711 @default.
• W2996319504 hasConceptScore W2996319504C2779343474 @default.
• W2996319504 hasConceptScore W2996319504C2781197716 @default.
• W2996319504 hasConceptScore W2996319504C2908647359 @default.
• W2996319504 hasConceptScore W2996319504C535046627 @default.
• W2996319504 hasConceptScore W2996319504C55493867 @default.
• W2996319504 hasConceptScore W2996319504C71924100 @default.
• W2996319504 hasConceptScore W2996319504C86803240 @default.
• W2996319504 hasConceptScore W2996319504C99454951 @default.
• W2996319504 hasFunder F4320306828 @default.
• W2996319504 hasFunder F4320309555 @default.
• W2996319504 hasFunder F4320315957 @default.
• W2996319504 hasFunder F4320337362 @default.
• W2996319504 hasIssue "4" @default.
• W2996319504 hasLocation W29963195041 @default.
• W2996319504 hasLocation W29963195042 @default.
• W2996319504 hasLocation W29963195043 @default.

• next